Abeona Rett Agreement was Taysha Gene Therapies’s largest revenue line in fiscal 2023, bringing in $13.20M of $15.50M (85%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2022 | FY 2023 |
|---|---|---|
| Abeona Rett Agreement | $2.50M | $13.20M |
| Option Agreement For Gan | — | $2.30M |
| Total | $2.50M | $15.50M |
Taysha Gene Therapies brought in $15.50M from its two revenue lines in fiscal 2023, the year ended December 31, 2023. Taysha Gene Therapies regrouped these revenue lines after fiscal 2022, so the total does not compare directly with that year's $2.50M. Abeona Rett Agreement was the largest at $13.20M (85.2%), ahead of Option Agreement For Gan at $2.30M (14.8%).
Taysha Gene Therapies began breaking out Option Agreement For Gan in fiscal 2023, when it brought in $2.30M.
Taysha Gene Therapies (TSHA) reports its revenue by collaborative arrangement and arrangement other than collaborative. In fiscal 2023, Abeona Rett Agreement was its largest revenue line, bringing in $13.20M (85.2% of the total), followed by Option Agreement For Gan at $2.30M (14.8%).
Abeona Rett Agreement was Taysha Gene Therapies' largest revenue line in fiscal 2023, bringing in $13.20M, or 85.2% of the $15.50M total across its two revenue lines.
Every figure comes from Taysha Gene Therapies' annual financial filings, as reported. Each line keeps the name Taysha Gene Therapies gives it, and years follow its fiscal calendar.
Taysha Gene Therapies' revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2022, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.